Avantor’s Mary Blenn outlines five considerations for biopharma supply chain localization, from customer demand visibility to cost, consistency and redundancy.
Mary Blenn
Advertisement
Mary Blenn is executive vice president and chief operating officer at Avantor.
Articles by Mary Blenn
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Inside Cencora's Approach to AI-Driven Demand Sensing
2
What AI Changes, and Doesn’t, in Exception Handling
3
BMS’s Kevin Cook on Moving CMO Partnerships Beyond Transactions
4
Pharma Pulse: DHL's New Cold Chain Corridors and Walmart's $0 Prescription Tier
5